Company / Operating Income per Share
VYNE Therapeutics Inc. Operating Income per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$2.94
FY2025
5-year range
-$13.07 / -$2.08
FY2021-FY2025
Trend
-41.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income per Share has fluctuated over the past 8 years, ranging from $-13.07 in FY2022 to $-1.27 in FY2019.
Based on SEC 10-K filings.
-2.94 in FY2025.
Improved from $-10.62 to $-2.94 over the past 2 years.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income per share decreased 41.8% year-over-year.
- Peak operating income per share was recorded in FY2019.
- Lowest operating income per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.94 | -41.8% |
| FY2024 | -$2.08 | +80.5% |
| FY2023 | -$10.62 | +18.8% |
| FY2022 | -$13.07 | -123.6% |
| FY2021 | -$5.85 | +28.8% |
| FY2020 | -$8.21 | -544.7% |
| FY2019 | -$1.27 | +52.9% |
| FY2018 | -$2.70 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026